What is Roth Capital’s Forecast for CELZ FY2028 Earnings?

Posted by Teresa Graham on Feb 15th, 2025

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ – Free Report) – Equities researchers at Roth Capital reduced their FY2028 earnings per share estimates for Creative Medical Technology in a note issued to investors on Wednesday, February 12th. Roth Capital analyst J. Aschoff now anticipates that the company will earn $6.02 per share for the year, down from their previous forecast of $6.34. The consensus estimate for Creative Medical Technology’s current full-year earnings is ($3.19) per share. Roth Capital also issued estimates for Creative Medical Technology’s FY2029 earnings at $7.83 EPS.

Creative Medical Technology Stock Up 3.3 %

Shares of NASDAQ:CELZ opened at $4.74 on Friday. Creative Medical Technology has a 52-week low of $1.96 and a 52-week high of $10.28. The stock’s fifty day simple moving average is $2.66 and its 200-day simple moving average is $3.07. The company has a market capitalization of $8.29 million, a P/E ratio of -1.25 and a beta of 1.85.

Institutional Trading of Creative Medical Technology

A hedge fund recently bought a new stake in Creative Medical Technology stock. Geode Capital Management LLC bought a new position in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ – Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,308 shares of the company’s stock, valued at approximately $25,000. Geode Capital Management LLC owned 0.59% of Creative Medical Technology at the end of the most recent quarter. Hedge funds and other institutional investors own 1.42% of the company’s stock.

About Creative Medical Technology

(Get Free Report)

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.